Condition: Gastroenteropancreatic Neuroendocrine Tumors · Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (albumin bound) combined with octreotide long-acting injection in patients with unresectable or recurrent GEP-NETs.
This description comes directly from the study's public registry record.
Clinical Trials Information Group officer · 86-0311-69085587 · ctr-contact@cspc.cn
Always discuss trial participation with your own doctor first.
| Chinese PLA General Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07165886